Actavis Launches Generic Specialty Injectables for USBy
Actavis has launched a portfolio of generic specialty injectable medications to be marketed to hospitals across the United States. Actavis will begin marketing approximately 20 injectable products across a number of therapeutic categories in the US.
Some of the launched products include several generic injectables for oncology including versions of Gemzar (gemcitabine), Taxotere (docetaxel), Campostar (irinotecan), and Zometa (zoledronic acid). Actavis also has a specialty injectable pipeline, with approximately 20 new filings under review at the US Food and Drug Administration as well as more than 50 additional projects currently in development.
Many of Actavis’ generic specialty injectable products were previously marketed in the US by Sagent Pharmaceuticals, Inc. under a manufacturing and supply agreement originally signed by the companies in 2010. Actavis regained US marketing rights to the products following the expiration of the Sagent agreement on December 31, 2014.